European regulators cleared Fractyl Health for a clinical trial of its GLP-1 gene therapy candidate, positioning the company in the race to replace chronic GLP-1 injections and pills with a potentially one-time treatment. The report frames the move as part of a broader pipeline effort to deliver long-acting metabolic therapy through gene-based delivery. The decision adds to momentum around GLP-1 replacement approaches, where developers are trying to translate durable metabolic effects from earlier-stage data into clinical evidence. It also signals regulatory willingness to test gene therapy strategies in metabolic disease. The report did not specify the trial phase, geography, or start date details.